Physician profile
Peter C Roblejo
NPI 1194772095
$3,247.75
in general payments reported to CMS, 2019-2025
33 companies · $724 in 2025
The $724 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $285 · 2021: $365 · 2022: $381 · 2023: $494 · 2024: $725 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,943.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,333.77 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Lilly USA, LLC | $231.74 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Novartis Pharmaceuticals Corporation | $207.42 | 2019-2021 | |
| Mdd US Operations, LLC | $203.91 | 2023-2025 | Apokyn, Xadago, Xadago |
| Lundbeck LLC | $197.21 | 2022-2025 | Rexulti, Vyepti |
| Amgen INC. | $130.47 | 2019-2021 | |
| Pfizer INC. | $96.61 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $77.08 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $76.96 | 2019-2022 | |
| Argenx US, INC. | $60.37 | 2022-2025 | Vyvgart Hytrulo |
| Eisai INC. | $60.31 | 2025 | |
| Ge Healthcare | $57.41 | 2019-2024 | |
| Allergan, INC. | $56.83 | 2020 | |
| Sk Life Science, INC. | $44.50 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $39.83 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $38.60 | 2023-2024 | Valtoco |
| Axsome Therapeutics, INC. | $33.89 | 2025 | Symbravo |
| Teva Pharmaceuticals USA, INC. | $30.80 | 2023-2024 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $28.56 | 2024-2025 | Rexulti |
| Impel Pharmaceuticals INC. | $26.49 | 2023 | Trudhesa |
| Biogen, INC. | $25.88 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.40 | 2022 | |
| Averitas Pharma INC. | $18.94 | 2023 | Qutenza |
| Ucb, INC. | $17.49 | 2022 | |
| Neurocrine Biosciences, INC. | $16.98 | 2025 | |
| Aprecia Pharmaceuticals, LLC | $15.94 | 2021 | |
| Merck Sharp & Dohme LLC | $15.00 | 2020 | |
| Vertical Pharmaceuticals, LLC | $14.49 | 2020 | |
| Glaxosmithkline, LLC. | $14.03 | 2021 | |
| Bausch Health US, LLC | $14.01 | 2021 | |
| Jazz Pharmaceuticals INC. | $13.54 | 2019 | |
| Acadia Pharmaceuticals INC | $12.56 | 2022 | |
| Medtronic USA, INC. | $11.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Roblejo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.